Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.55 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 10/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691450 | 0.90 | PTK2 (0.54) | PTK2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL691468 | 0.89 | PTK2 (0.63) | PTK2KCNJ6KCNJ5KCNJ3SRC | |
| SCHEMBL691083 | 0.82 | PTK2 (0.66) | PTK2KCNJ6KCNJ5KCNJ3KCNH2 | |
| SCHEMBL691926 | 0.81 | PTK2 (0.52) | PTK2KCNJ6KCNJ5KCNJ3SRC | |
| SCHEMBL689984 | 0.80 | PTK2 (0.64) | PTK2KCNJ6KCNJ5KCNJ3KCNH2 | |
| SCHEMBL691542 | 0.78 | PTK2 (0.82) | PTK2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL692459 | 0.76 | PTK2 (0.82) | PTK2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL691295 | 0.74 | PTK2 (0.78) | PTK2KCNJ6KCNJ5KCNJ3LMNA | |
| SCHEMBL691389 | 0.74 | PTK2 (0.64) | PTK2KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL691451 | 0.74 | MAPK1 (0.38) | PTK2NPC1LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | disclosed |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2015-09-24 | — | — | US | disclosed |
| US-9012479-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2421537-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GlaxoSmithKline LLC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885KCNJ6 939/4885KCNJ5 630/4885 |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885KCNJ6 939/4885KCNJ5 630/4885 |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885KCNJ6 939/4885KCNJ5 630/4885 |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885KCNJ6 939/4885KCNJ5 630/4885 |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885KCNJ6 939/4885KCNJ5 630/4885 |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885KCNJ6 939/4885KCNJ5 630/4885 |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885KCNJ6 939/4885KCNJ5 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.